CHAPEL HILL -- Chapel Hill-based pharmaceutical company Pozen on Wednesday reported a net loss for 2012 of $25.3 million, down from a net income of $42.3 million in the prior ...
Read more
The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in Europe.Pozen licensed the compound MT 400 to German central nervous system therapies company Desitin in ...
Read more
Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, but for all of those commercialization pains, the drug has become an unexpected regulatory beacon ...
Read more
April 30, 2012 2:52 pm by Frank Vinluan | 0 Comments
Pozen (NASDAQ:POZN), now prepping to file a new drug application for its safer form of aspirin, has run into a slight regulatory headache.The company had looked on track way for ...
Read more
March 22, 2012 11:18 am by Frank Vinluan | 0 Comments
The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed in clinical trials that it causes fewer ulcers compared to aspirin alone.With those positive phase ...
Read more
February 28, 2012 3:03 pm by Frank Vinluan | 0 Comments
Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was ...
Read more
February 14, 2012 11:40 am by Frank Vinluan | 1 Comments
For a glimpse into social media’s coming role in pharmaceutical sales and marketing, and the digital health of tomorrow, consider its use in Gatorade’s marketing today.The Gatorade Company maintains a ...
Read more
January 27, 2012 7:00 am by Frank Vinluan | 0 Comments
As drug partnering auditions go, Pozen (NASDAQ:POZN) has played this role before: The small drug developer flirts with a large pharmaceutical company who has the resources and the reach to ...
Read more
January 27, 2012 7:00 am by Frank Vinluan | 0 Comments
Pozen (NASDAQ:POZN) CEO John Platchetka likens the drug partnering process to a relay race. One runner at full speed finishes and hands the baton to another runner at full speed ...
Read more
December 21, 2011 10:52 am by Frank Vinluan | 0 Comments
The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food ...
Read more
November 28, 2011 12:01 pm by Frank Vinluan | 1 Comments
To understand why Pozen (NASDAQ:POZN) sold future U.S. royalty rights for migraine drug Treximet, its lead revenue-generating product, it helps to understand what the company is doing with its drug ...
Read more
November 25, 2011 5:54 pm by Stephanie Baum | 0 Comments
Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal.The terms of the deal give ...
Read more
November 4, 2011 1:35 pm by Frank Vinluan | 1 Comments
If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance.Although Chapel Hill, ...
Read more
October 4, 2011 6:34 pm by Frank Vinluan | 0 Comments
Digital drug marketing has been pharmaceutical company Pozen‘s (NASDAQ:POZN) mantra for much of this year. The Chapel Hill, North Carolina-based company has made clear that when it goes to market ...
Read more
September 16, 2011 4:32 pm by Frank Vinluan | 0 Comments
The digital communication consumers favor today to discuss retail products and food might have more to say about the future of pharmaceutical marketing than the still-ubiquitous television commercials promoting the ...
Read more
